Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein
- 27 July 2000
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 2 (4) , 250-259
- https://doi.org/10.1002/1521-2254(200007/08)2:4<250::aid-jgm113>3.0.co;2-3
Abstract
Background The inherent limitations of [E1‐]Ad vectors as gene therapy vehicles suggest that further modifications may improve their overall performance profiles. However, Ad vector modifications can have untoward effects on their basic biology, e.g., some helper‐virus dependent Ad vectors have been found to be unstable without the presence of preterminal protein (pTP) activities. Despite this concern, we generated a new class of helper‐virus independent Ad vector that was multiply deleted for the E1, polymerase, and pTP genes, and investigated the ramifications of these deletions upon several vector performance parameters. Methods The construction and propagation of an [E1‐, polymerase‐, pTP‐]Ad vector was achieved with the use of trans‐complementing cells co‐expressing the Ad E1, polymerase and pTP genes. Results High titer production of the [E1‐, polymerase‐, pTP‐]Ad vector was successfully accomplished via conventional Ad purification techniques. This unique class of Ad vector was capable of long‐term gene transfer in vivo (despite lacking pTP functions) that was concomitant with a significantly decreased hepatic toxicity. Conclusions Previous studies had suggested that Ad genome persistence in vivo may be dependent upon the presence of low level vector genome replication and/or pTP functions. Our results suggest that [E1‐, polymerase‐, pTP‐]Ad vectors can overcome these barriers. The further benefits afforded by the use of this class of Ad vector (increased cloning capacity, high level growth, decreased propensity to generate replication competent Ad (RCA), decreased toxicity) suggests that they will be highly beneficial for use in several aspects of human gene therapy. Copyright © 2000 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- Persistence of an [E1-, Polymerase-] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent MiceHuman Gene Therapy, 1999
- Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using δ-Sarcoglycan Gene TransferMolecular Cell, 1998
- Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivoNature Biotechnology, 1997
- Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expressionGene Therapy, 1997
- Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vectorGene Therapy, 1997
- Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapyGene Therapy, 1997
- Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cellsHuman Molecular Genetics, 1996
- Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus–mediated transfer of the VLDL receptor geneNature Genetics, 1996
- Characterization of an Adenovirus Gene Transfer Vector Containing an E4 DeletionHuman Gene Therapy, 1995
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994